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Background: Rats exhibit extremely limited motor function recovery after total transection of the spinal cord (SCT).
We previously reported that SM-216289, a semaphorin3A inhibitor, enhanced axon regeneration and motor function
recovery in SCT adult rats. However, these effects were limited because most regenerated axons likely do not connect
to the right targets. Thus, rebuilding the appropriate connections for regenerated axons may enhance recovery. In
this study, we combined semaphorin3A inhibitor treatment with extensive treadmill training to determine whether
combined treatment would further enhance the “rewiring” of regenerated axons. In this study, which aimed for
clinical applicability, we administered a newly developed, potent semaphorin3A inhibitor, SM-345431 (Vinaxanthone),
using a novel drug delivery system that enables continuous drug delivery over the period of the experiment.
Results: Treatment with SM-345431 using this delivery system enhanced axon regeneration and produced significant,
but limited, hindlimb motor function recovery. Although extensive treadmill training combined with SM-345431
administration did not further improve axon regeneration, hindlimb motor performance was restored, as evidenced by
the significant improvement in the execution of plantar steps on a treadmill. In contrast, control SCT rats could not
execute plantar steps at any point during the experimental period. Further analyses suggested that this strategy
reinforced the wiring of central pattern generators in lumbar spinal circuits, which, in turn, led to enhanced motor
function recovery (especially in extensor muscles).
Conclusions: This study highlights the importance of combining treatments that promote axon regeneration with
specific and appropriate rehabilitations that promote rewiring for the treatment of spinal cord injury.
Keywords: Axonal regeneration, Semaphorin3A, Inhibitor, Rehabilitation, Rewiring, Drug delivery systemBackground
Severe spinal cord injuries (SCI) in adult mammals result
in various deficits throughout life. The limited capability
of axons to regenerate in the central nervous system
(CNS) is thought to be the main reason for these lasting
deficits. Previous studies have suggested that both ex-
trinsic and intrinsic factors in the CNS contribute to this
incapacity for axonal regeneration [1-4]. Several distinct
extrinsic molecules have been proposed to hinder axonal* Correspondence: hidokano@a2.keio.jp; masa@a8.keio.jp
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unless otherwise stated.regeneration, including CNS myelin-associated proteins
(MAG, Nogo, OMgp) [5-9], chondroitin sulphate proteo-
glycans [10,11], semaphorin3A [12,13] and RGM (repulsive
guidance molecule) [14,15]. Neutralizing one (or several) of
these molecules enhances axonal regeneration and results
in some degree of functional recovery [10,16,17]. Until
recently, it remained unknown whether neutralizing
semaphorin3A would also lead to axonal regeneration and
motor function recovery, in part because semaphorin3A
deficiency is lethal [18]. Thus, we previously developed
a selective and potent semaphorin3A inhibitor called
SM-216289 [19] that selectively inhibits semaphorin3A
signaling both in vitro and in vivo [20]. Administration of
SM-216289 to adult rats after total spinal cord transectionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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recovery [20]. In addition, axonal regeneration and func-
tional recovery have now been observed after several
treatments that block 1 or more axonal growth inhibitors
(including SM-216289). However, these effects are moderate
at best, presumably because most of the regenerated axons
do not connect with the correct targets [21]. Thus, re-
building the appropriate connections of regenerated axons
in lesioned spinal cords remains an important unresolved
issue.
Body weight-supported treadmill training induces plastic
changes in lesioned spinal cords and is useful for maximiz-
ing residual locomotor function after moderate SCI [22,23].
Furthermore, even after severe SCI, treadmill training
partially improves hindlimb coordination [24] by inducing
plasticity in specific spinal locomotor circuits called “cen-
tral pattern generators” (CPGs). More specifically, these
plastic changes have been shown to result in the recovery
of plantar step walking in cats [25] and neonatal rats [26].
Furthermore, SCT adult rats partially recover plantar
step walking when treadmill training is combined with
other appropriate treatments, such as epidural electrical
stimulation [27], pharmacological treatments [24] or cell
transplantation [28]. Thus, with specific and appropriate
rehabilitation, spinal cord CPGs can be reorganized, and
functionally appropriate connections between CPGs and
regenerated (or residual) axons can be rebuilt. Therefore,
we hypothesized that extensive treadmill training would
assist in the correct wiring of axons regenerated by sema-
phorin3A inhibitor treatment and that this rewiring may
contribute to further motor functional recovery after SCT.
However, several issues, including drug delivery, remain
to be resolved before semaphorin3A inhibitors can be
used in the clinic. In an attempt to resolve these issues,
we developed a novel selective semaphorin3A inhibitor,
SM-345431 (Vinaxanthone), which demonstrates physico-
chemical properties equivalent to those of SM-216289 but
also improvements that should allow for the development
of a higher quality pharmaceutical product. Additionally,
we developed a novel drug delivery system (DDS) utilizing
a silicone sheet. With future clinical applications in mind,
we chose to evaluate SM-345431 with this novel DDS.
We observed that, consistent with our previous study
[20], SM-345431 treatment enhanced axon regeneration
and resulted in significant, but limited, hindlimb motor
function recovery. Although extensive treadmill training
with SM-345431 administration did not further improve
axon regeneration, hindlimb motor performance was re-
stored, as evidenced by the execution of plantar steps on a
treadmill using a body support system (BSS). Moreover,
immunohistological analysis suggested that SM-345431
administration with treadmill training reinforced the wir-
ing of CPGs in lumbar spinal circuits and led to enhanced
motor function recovery, especially in extensor muscles.Results
Evaluation of a novel DDS and the activity of SM-345431
in vitro
In our previous study, we used an osmotic mini-pump
to deliver the semaphorin3A inhibitor SM-216289 [20].
However, in clinical practice, this type of invasive drug
delivery method is not ideal. Therefore, we developed a
novel DDS that utilizes a silicone matrix to continuously
deliver SM-345431 (a newly developed semaphorin3A in-
hibitor) intrathecally. We evaluated the drug release pro-
file of SM-345431 in this new silicone matrix preparation
and the potency of SM-345431-mediated semaphorin3A
inhibition in vitro (Figure 1). SM-345431 exhibited sema-
phorin3A inhibiting activity with an IC50 of 0.1-0.2 μM in
growth cone collapse assays using E8 chick and E14 rat
dorsal root ganglia (DRG) (Figure 1A). When chick embry-
onic DRG explants and semaphorin3A-expressing COS7
cell aggregates (semaphorin3A-COS) were co-cultured
in a collagen gel, the neurites of the DRG explants grew
away from the semaphorin3A-COS, as shown in Figure 1B.
However, when DRG explants and semaphorin3A-COS
were co-cultured in the presence of SM-345431, radial ex-
tensions of the neurites were observed, which suggests
that the chemo-repulsive effects of semaphorin3A were
blocked by SM-345431 in a dose-dependent manner
(Figure 1B). We also evaluated the selectivity of SM-345431
for semaphorin3A inhibition by examining the pharmaco-
logical profile of SM-345431 (Tables 1 and 2). As shown in
these tables, the IC50 value for semaphorin3A inhibition
was substantially lower than the other IC50s, which sug-
gested that SM-345431 is a highly selective semaphorin3A
inhibitor. To examine the semaphorin3A inhibiting activity
of SM-345431 while it was being released from the silicone
matrix (SM-345431-silicone), 1 mg of a silicone sheet
containing 100 μg SM-345431 was placed into collagen
gel cultures containing DRG explants and semaphorin3A-
COS (Figure 1C). Assuming that 5% of the SM-345431
was released and uniformly diffused throughout the culture
during the 2 days of incubation, the final concentration
of SM-345431 was approximately 5 μM, which is a large
enough dose to inhibit semaphorin3A activity. Radial
neurite extension was observed in cultures with SM-
345431-silicone but not in those with control silicone,
indicating that semaphorin3A activity had been inhibited
by SM-345431. We also measured the cumulative percent-
age of released doses of SM-345431 using this DDS over
2 months in vitro (Figure 1E) and found that this DDS
released a constant dose of SM-345431 and was stable
in vitro. When 7 mm × 5 mm × 0.3 mm sheets were used,
the amount of drug release stabilized at approximately
10 μg/day after an initial peak of drug release that occurred
over the first 2 days (Figure 1F). For the in vivo study, we
trimmed the silicone sheet into 3 mm × 3 mm × 0.3 mm
pieces to fit the injury site following SCT (Figure 1G-I).
Figure 1 Preparation of the SM-345431 silicone DDS and in vitro release study. (A) Analysis of the inhibitory activity of SM-345431 in the
growth cone collapse assay using E8 chick and E14 rat DRGs. (B) Collagen co-culture assay using E8 chick DRGs and semaphorin3A-expressing
COS7 cell aggregates. (C) Pictures showing the effects of SM-345431-silicone or control-silicone in the collagen gel. (D) Schematic illustration of
drug release from the matrix silicone preparation; the drug is dissolved in water, permeates into the preparation and is then released. The rate of
water permeation into the silicone matrix is controlled by various additives, and the proportions of these additives included in the DDS control
the variations in the drug release profile. The preparation used here contained the water-soluble additives listed in the table (D). Stable and linear
release of SM-345431 was observed for up to 2 months as shown in (E) and (F). (E, F) SM-345431 release curve for the preparation. The linear
cumulative percent release curve at 2 months (E) and the stable release dosage per day (F) are shown for the administration of SM-345431
using this novel DDS. (G) Exposed intact spinal cord. (H) Transected spinal cord. (I) The novel DDS we employed. A silicone sheet containing
SM-345431 was placed onto the transected site of the spinal cord. The system allowed for stable and continuous release of the semaphorin3A
inhibitor throughout the experimental period.
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was calculated as 0.5-0.7 μg/day, and this dose was similar
to the dose of the semaphorin3A inhibitor (SM-216289)
[19] that we administered using osmotic mini pumps in
our previous study [20]. Therefore, the newly developed
DDS allowed stable and continuous release of the newly
developed, potent semaphorin3A inhibitor SM-345431.
SM-345431 delivery via the novel DDS enhanced axonal
regeneration
To examine the regeneration of axons after SM-345431
treatment and SM-345431 treatment combined with exten-
sive treadmill training, we evaluated axons in the injuredspinal cord with immunostaining using antibodies against
GAP43 and serotonin (5-HT) (Figure 2), GAP43 is widely
used as a marker for regenerated axons. In both treat-
ment groups, a marked increase in the number of GAP43-
positive axons was observed at the epicenter of the injury
(Figure 2D-F) and in the surrounding area (Figure 2G-I).
Compared with the control group, the number of GAP43
axons was significantly increased in both the SM-345431
treatment group and the combined treatment group, espe-
cially at 1 mm caudal to the injury epicenter (Figure 2J).
No significant difference was observed between the 2
treatment groups. Thus, administration of the semaphor-
in3A inhibitor SM-345431 using this DDS enhanced axonal
Table 1 Pharmacological profile of SM-345431 (part 1)
Enzymes IC50 (μm)
Semaphorin 0.1-0.2
Matrix Metalloproteinase-1 (MMP-1) >10
Matrix Metalloproteinase-7 (MMP-7) 10
Matrix Metalloproteinase-2 (MMP-2) >10
Matrix Metalloproteinase-3 (MMP-3) >10








Protein Tyrosine Phosphatase, CD45 >10
Protein Tyrosine Phosphatase, PTP1B >10
Protein Tyrosine Phosphatase, PTP1C >10
Protein Tyrosine Phosphatase, T-Cell >10














Cell proliferation, B-Cell+LPS >10
Cell proliferation, T-Cell+Con A >10
Mediator release, IL-1beta >10
Mediator release, IFN-gamma >10
Mediator release, IL-10 >10
Mediator release, IL-2 >10
Mediator release, IL-4 >10
Mediator release, IL-5 >10
Mediator release, IL-6 >10
Mediator release, TNF-alfa, PBML >10
Transcription response, NF-AT >10
Transcription response, NF-kB >10
Summary of the IC50 values for binding assays of various receptors and ion
channels, and IC50 values for the inhibition of various enzymes. The IC50
value for semaphorin3A inhibition was extremely low compared to that of the
other factors.








































Summary of the IC50 values revealed by inhibition tests for various kinases.
The data in Tables 1 and 2 suggest that SM-345431 was highly selective for
semaphorin3A inhibition.
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was observed when SM-345431 treatment was combined
with treadmill training.
Figure 2 SM-345431 enhanced axonal regeneration in vivo, but combined treatment had only a limited effect on further axon
regeneration. (A-I) Sagittal sections from SCT rats immunostained for GAP-43. Low-magnification images of the control (A), SM-345431 (B) and
combined treatment (C) groups. Scale bars = 500 μm. (D-F) Magnified images of the boxed areas shown in A-C. Scale bars = 10 μm. (G-I) Additional
magnified images of the boxed areas shown in A-C. Scale bars = 10 μm. (J) Quantitative analysis of GAP-43-positive areas at 1 mm rostral to the lesion,
1 mm caudal to the lesion and at the epicenter of the lesion. Immunohistochemistry was performed using DAB with nickel enhancement. *P < 0.05,
**P < 0.01. Statistical analyses were performed using one-way ANOVA and Bonferroni post hoc tests. Data are represented as the mean ± S.E.M. (K-P)
Sagittal sections of SCT rats double-stained for 5-HT and GFAP. Scar tissue is outlined by GFAP staining, which also allowed for confirmation of total
transection of the spinal cord in each animal. (K-M) Low-magnification images of the control (K), SM-345431 (L) and combined treatment (M) groups.
Scale bars = 500 μm. (N-P) Magnified images of the boxed areas shown in K-M. Scale bars = 10 μm. Arrowheads represent 5-HT-positive (serotonergic)
axons. (Q-S) Quantitative analyses of 5-HT-positive axons that penetrated into the scar tissue. (Q) Quantitative analysis of the number of 5-HT-positive
axons that penetrated into the lesion site. (R,S) Quantitative analysis of the 5-HT-positive area within the scar tissue area. Immunohistochemistry was
performed by double-staining using DAB with or without nickel enhancement. The left side is rostral in all images. **P < 0.01. Statistical analyses were
performed using a Kruskal-Wallis H test. Data represent the mean ± S.E.M.
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immunohistochemistry against serotonin (5-HT), contrib-
ute to functional locomotor control, and regeneration of
these axons leads to substantial enhancement of motor
function recovery [28]. Therefore, we also evaluated the
regeneration of raphespinal tract axons using a GFAP
antibody to delineate scar tissue at the injury site and a
5-HT antibody to visualize raphespinal axons. In control
animals, 5-HT-positive axons were restricted to the area
rostral to the transected site, and few 5HT-positive axonsentered the GFAP-negative scar tissue area (Figure 2K,N).
Interestingly, significantly more 5-HT-positive axons
penetrated the GFAP-negative scar tissue area after SM-
345431 treatment and combined treatment as compared
to the control conditions (Figure 2K-S). Because we used a
total transection model in this study, the 5-HT-positive
axons that penetrated the GFAP-negative scar tissue in
the treatment groups were regarded as regenerated axons
(Figure 2L-P). Cortico-spinal tract (CST) axons are known
to be incapable of regeneration after transection, even
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We next evaluated the regeneration of CST axons using
the anterograde tracer biotinylated dextran amine (BDA).
We first confirmed sufficient labeling efficiency of BDA
tracing in each animal, and no obvious CST regeneration
beyond the lesion epicenter was observed in either the
control or the semaphorin3A inhibitor treatment group,
which is consistent with our previous paper’s findings [20]
(Figure 3). Moreover, no clear CST regeneration beyond
the lesion epicenter was observed in the combined treat-
ment group (Figure 3).
SM-345431 enhanced angiogenesis and remyelination
Semaphorin3A suppresses VEGF-induced angiogenesis,
and inhibition of semaphorin3A leads to enhancement
of angiogenesis [29]. This phenomenon occurs because
semaphorin3A and VEGF share the same receptor, neuro-
pilin1 [30]. In addition, blood vessels are believed to play
important roles in tissue repair and axonal regeneration
after SCI [31-33]. Therefore, we analyzed the effects of
SM-345431 treatment (using our DDS) on angiogen-
esis. For immunohistochemistry, we used the anti-RECA-1
antibody, which is known to enable visualization of
blood vessels and migrating endothelial cells in rats [32]
(Figure 4A). RECA-1-positive areas 3 mm caudal to the le-
sion epicenter were significantly increased after combinedFigure 3 Histological analyses of the treatment effects on CST regenera
representative axial section of the spinal cord at the C4 level (rostral to the les
(caudal to the lesion site) (Scale bars = 500 μm). Based on these sections, we
sufficient. A, B and C show representative sagittal sections of the BDA staining
Similarly, F/G show magnifications of the areas in B, and the images in H/I ar
100 μm in D-I. No obvious CST regeneration beyond the lesion epicenter was
performed using one-way ANOVA and Bonferroni post hoc analyses. Data are
other sagittal sections from each group. Scale bars = 1,000 μm in the imagestreatment (Figure 4C, P < 0.05). Based on their morphology,
thick-walled blood vessels with lumen diameters larger than
20 μm are thought to be newly formed blood vessels [34]
(Figure 4A,B, arrows). Consistent with previous reports
[34,35], these thick-walled blood vessels were rarely
observed in the intact spinal cord. In comparison to the
control group, the total immunostained areas of vessels
with lumen diameters larger than 20 μm were significantly
increased in both the SM-345431 and combined treatment
groups 3 mm rostral/caudal and 1 mm rostral/caudal to
the lesion epicenter (Figure 4D). Furthermore, the effects
of angiogenesis tended to be enhanced in the combined
treatment group compared to the SM-345431 treatment
group, but this difference did not reach statistical signifi-
cance (Figure 4C,D). Thus, SM-345431 treatment signifi-
cantly increased the number of newly formed blood vessels.
Semaphorin3A also inhibits oligodendrocyte precursor
cell recruitment and influences remyelination [36]. Using
immunohistochemistry and electron microscopy, we next
characterized the axons at the lesion sites after SM-345431
treatment in greater detail. In the SM-345431 treatment
group, we observed substantial numbers of myelinated
GAP43-positive axons at the lesion site (Figure 4H-J),
whereas myelinated GAP43-positive axons were rarely
observed at the lesion site in the control SCT group
(Figure 4E-G). Based on their morphologies, the thintion in the injured spinal cord using BDA staining. J shows a
ion site), and K shows a representative image of a section at the L4 level
confirmed that the labeling efficiency of BDA tracing in each animal was
in each group. D/E show magnified images of the boxed area in A.
e magnifications of the areas in C. Scale bars = 1,000 μm in A-C and
observed in any of the groups examined (L). Statistical analyses were
presented as the mean ± S.E.M. The images in M are representative of
on left side ofM and 100 μm in the magnified images ofM.
Figure 4 (See legend on next page.)
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Figure 4 Histological analyses of the treatment effects on microvasculature and remyelination in the spinal cord. (A) Visualization of
blood vessels using an anti-RECA-1 antibody. Images in the upper row are low-magnification views of the gray matter areas of sagittal sections
immunostained for RECA-1 at 1 mm caudal to the transected site. Scale bars = 50 μm. Images in the lower row are high-magnification views that
correspond to the boxed areas in the upper row images. Scale bars = 50 μm. (B) Representative image of a blood vessel with a lumen with a diameter
larger than 20 μm (arrow), which indicated newly formed blood vessels following injury. Scale bars = 50 μm. Arrows in (A) also represent blood vessels
with lumen diameters larger than 20 μm. The left side is rostral (A,B). (C) Quantitative analysis of RECA-1-positive areas in each group. (D) Quantitative
analysis of the total areas of RECA-1-positive blood vessels with lumen diameters larger than 20 μm. *P < 0.05, **P < 0.01. Statistical analyses were
based on one-way ANOVA and Bonferroni post hoc analyses. (E-M) Analyses of remyelination performed using immunohistochemistry against MBP or
electron microscopy 12 weeks post-injury. (E,F,H,I,K,L) Reconstructed confocal images showing double staining (sagittal sections) for MBP (green) and
GAP43 (red) in the control group (E,F), SM-345431 treatment group (H,I) and combined group (K, L). F, I and L show magnified images of the boxed
areas in E, H and K, respectively. Scale bars = 100 μm. The arrow in F shows a non-myelinated (MBP-negative) GAP-43-positive axon, and the arrows in
I and L show myelinated (MBP-positive) GAP-43-positive axons. The left side is rostral. (G,J) Electron microscopic images of transverse sections from
the control group (G) and SM-345431 treatment group (J) at the lesion site. Scale bars = 2 μm. (N) Statistical analysis of the number of myelinated
(MBP-positive) GAP-43-positive axons in each group, which were analyzed by immunohistochemistry. *P < 0.05, **P < 0.01. Statistical analyses were
performed using one-way ANOVA and Bonferroni post hoc analyses. All the data are represented as the mean ± S.E.M.
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likely the result of remyelination (Figure 4H-J). While
SM-345431 treatment significantly enhanced the remye-
lination of axons (Figure 4N), additional remyelination
was not observed in the SM-345431 plus treadmill training
combined group (Figure 4K-N).
Combining SM-345431 with treadmill training reinforced
specific spinal locomotor circuitry and synaptic connectivity
Functional locomotor recovery in spinal cord models is
critically dependent on supraspinal connections to CPGs
[37]. To examine the combined effects of SM-345431
treatment and treadmill training on the reconstruction
of spinal cord circuitry at the lumbar level, we performed
immunostaining for c-Fos [38] and synapsin-1 [39,40].
c-Fos is widely used as a marker to measure the extent
of the supraspinal drive of specific spinal locomotor
circuitries because c-Fos expression in neurons normally
increases when after the control of spinal locomotor
circuitries’ circuitry control is lost [41,42]. Consistent with
previous studies, c-Fos expression in nuclei (c-Fos +
nuclei) was observed in all rats in levels L1-L5 (Figure 5A-C)
[43]. In addition, the number of c-Fos + nuclei tended to
be lower at the L1-L5 levels in SM-345431-treated SCI
rats than in control SCI rats, but this difference did not
reach statistical significance (Figure 5B). Interestingly, the
combined treatment group showed a statistically signifi-
cant decrease in the number of c-Fos + nuclei compared
to control SCT rats at the L4 and L5 levels (Figure 5B,
P < 0.01). We also compared the rostral (L1 + L2) and
caudal (L4 + L5) segments of the lumbar enlargement to
examine the overall effects of combinatorial treatment
(Figure 5C). Compared to the intact group (normal rats),
control SCT rats showed a significant increase in c-Fos +
nuclei counts in the caudal segments of the lumbar en-
largement (L4-5), which is consistent with previous re-
ports (Figure 5C, P < 0.01) [24]. On the other hand, after
combined treatment, the caudal segments of the lumbarenlargement showed significantly decreased c-Fos + nuclei
counts (Figure 5C, P < 0.01) as compared to control SCT
rats. The number of c-Fos + nuclei also tended to be
decreased after SM-345431 treatment alone, although this
difference was not statistically significant (Figure 5C).
Thus, specific spinal locomotor circuitries, especially in
the caudal sections of the lumbar enlargement, were
considerably reinforced by combined treatment and, to
a lesser extent, by SM-345431 treatment alone.
Synapsin-1, a widely used presynaptic marker, has been
used to examine activity-dependent synaptic plasticity and
synaptic function [39,40]. In comparison to the control
and SM-345431 groups, a statistically significant increase
in synapsin-1 expression was observed at the lumbar
enlargement level (Figure 5E-N) (P < 0.01 compared to the
control SCT group; P < 0.05 compared to the SM-345431
group) in the combined treatment group. No statistically
significant difference was observed between the SM-345431
group and the control SCT group (P > 0.05). These results
indicated that, while SM-345431 treatment alone had a
limited effect, SM-345431 treatment combined with tread-
mill training significantly reinforced synaptic plasticity and
function at the lumbar enlargement level.
Taken together, these data suggest that reinforcement
of specific spinal locomotor circuitries and motor learning
occurred in the lumbosacral circuits of adult rats after
combined treatment. These effects were also observed, to
a lesser extent, after SM-345431 treatment alone.
SM-345431 promoted motor functional recovery and
combined treatment enhanced this recovery
Next, we investigated the hindlimb motor functions of
rats while they walked on a treadmill (induced by a robotic
device) using kinematic analysis. In the control SCT rats,
hindlimb motor functions showed almost no recovery
throughout the period of our experiments (3 months).
The SCT rats were unable to take any steps on a treadmill
even 3 months post-injury, whereas the treated animals
Figure 5 Immunohistochemical analyses of the effects of treatment on functional remodeling of spinal circuits and synaptic connectivity
at the lumbar enlargement. (A) Representative Camera Lucida drawings of c-Fos + nuclei in transverse sections at the L2 and L4 levels from control
rats, SM-345431 treatment rats, combined treatment rats and intact rats. (B) Average total numbers of c-Fos + nuclei at each level of the lumbar spinal
segment. (C) Average total number of c-Fos + nuclei in rostral (L1 + L2) and caudal (L4 + L5) lumbar enlargement segments. (D) Correlation analysis
between the total number of c-Fos + nuclei in all segments of the lumbar enlargement and step ability on the treadmill. SM-345431 treatment
produced a trend toward decreases in the average number of c-Fos + nuclei, although this trend was not statistically significant compared to
the control and SM-345431 treatment groups. However, the combined treatment produced a statistically significant decrease in the number of
c-Fos + nuclei, suggesting that specific spinal locomotor circuitry was reinforced by combining SM-345431 treatment with extensive treadmill
training. *P < 0.05, **P < 0.01. Statistical analyses were performed using one-way ANOVA and Bonferroni post hoc analyses. Data are presented
as the mean ± S.E.M. (E-M) Representative reconstructed confocal images of double staining (transverse section) for synapsin-1 and Tuj-1 in the
ventricolumnar area of the spinal cord (E-G: low-magnification images, H-M: high-magnification images). H-J and K-M show the upper and
lower boxed areas in E-G, respectively. Scale bars = 50 μm. (N) Quantitative analysis of synapsin-1 expression in the ventricolumnar motor
neuron area 3 months after SCT. *P < 0.05, **P < 0.01. Statistical analyses were performed using one-way ANOVA and Bonferroni post hoc
analyses. Data are presented as the mean ± S.E.M.
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performed Bonferroni post hoc analyses to examine the
differences in step length and step height between the
groups (Figure 6A) and found that motor function was
significantly better in SM-345431 rats than in control
SCT rats (Figure 6B-C). Furthermore, SM-345431 treatment
with treadmill training further improved motor perform-
ance as compared to no treatment (Figure 6B,C,D,E) or
SM-345431 treatment alone (Figure 6D,E). To evaluate
motor functions in greater detail, we examined the “step
cycle area”, which was calculated by multiplying the
average step length and average step height as previously
described [44] (Figure 6F). This parameter includes
elements of both the horizontal and vertical step planes
and can thus be regarded as a 2-dimensional evaluation of
each step taken. We again performed Bonferroni post hocanalyses to statistically compare the differences between
the groups. In the SM-345431-treated rats, a statistically
significant enhancement of the step cycle area was ob-
served in comparison to the control SCT rats (P < 0.05
at 3 months). Furthermore, the combined treatment re-
sulted in an even greater improvement in step cycle area
when compared to control SCT rats (P < 0.05 at the first
month, P < 0.01 at the second month, P < 0.01 at the
third month). As previously described [20], the control
SCT rats could not take any steps on the treadmill even
at 3 months post-injury (Figure 6G,H and Additional
file 1). Without extensive treadmill training, the effects of
SM-345431 treatment were moderate and did not result
in plantar step walking, even with the BSS (Figure 6G,H
and Additional file 1). However, when combined with
extensive treadmill training, SM-345431 treatment led
Figure 6 Detailed kinematic analysis of hindlimb motor performance on the treadmill. (A) Representative image of the analysis and a schematic
diagram of the step parameters. Collected kinematic data from each group showing the average step lengths (B), maximum step lengths (C), average
step heights (D), maximum step heights (E) and step cycle areas (F). All of these data were recorded and analyzed using a robotic device (Rodent Robot
3000; Robomedica Inc.). Each kinematic analysis was performed at 70% BWS and a speed of 1 cm/s over 1 min. C represents the control group, S
represents the SM-345431 group, and R represents the combined treatment group. *P < 0.05, **P < 0.01. C-S* indicates that a statistically significant
difference was observed between the control and SM-345431 groups at P < 0.05. Statistical analyses were performed using one-way ANOVA with
Bonferroni post hoc analyses. Data are presented as the means ± S.E.M. (G) Representative sequential pictures of steps taken during the first 4 s of the
analysis (BWS: 70%, speed: 3 cm/s). (H) Kinematic characteristics of the first step taken in each group. SM-345431 treatment enhanced motor function
recovery on the treadmill, especially in terms of the step length parameters. Combined treatment further enhanced the motor function recovery,
especially in terms of the step height and step cycle area parameters.
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exposed to the combined treatment achieved continuous
plantar step walking on a treadmill with the BSS for at
least 30 min (Figure 6G,H and Additional file 1).
Specifically, SM-345431 treatment improved locomotor
function on a treadmill after SCT particularly in terms of
the step length parameters (Figure 6B,C: average and max-
imum step lengths). Regarding the step height parameter,
the effect of SM-345431 treatment was moderate and
statistically insignificant (Figure 6D,E). However, when
SM-345431 treatment was combined with extensive tread-
mill training, greater enhancement was observed, and
this enhancement extended to the step height parameter
(Figure 6D,E; average and maximum step heights). Fur-
thermore, the incremental effects of the treatments over
time on motor function performance, specifically on step
height and step cycle area, did not reach a plateau by theend of the experimental period (3 months post-injury).
At this time, the incremental effects tended to be more
robust in the SM-345431 treatment group than in the
combined treatment group (Figure 6F: step cycle area).
Interestingly, we also discovered a statistically significant
correlation between the number of c-Fos + nuclei and
motor function (step cycle area) within each group; the
c-Fos + nuclei counts were inversely correlated with the
extent of functional motor recovery (Figure 5D; r = -0.501,
P < 0.05).
We next examined the extent to which the regenerated
axons at the lesion sites contributed to motor function re-
covery in each group. We performed re-transection of the
initial lesion site 12 weeks after the initial injury, and we
also performed the kinematic analysis before and after the
re-transectioning procedure. None of the step parameters
changed significantly in the control group, whereas the
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group after re-transection (Figure 7). Interestingly, greater
attenuations of step ability were observed in all analyzed
parameters in the combined treatment group after re-
transection, and some of these parameters (step height)
were statistically significant (Figure 7, average step height:
P < 0.01; maximum step height: P < 0.05). Thus, the regen-
erated axons at the lesion site contributed, at least partially,
to the enhancement of motor function recovery.
Discussion
With clinical applications in mind, we first sought to find
an appropriate and efficient way to deliver our semaphor-
in3A inhibitor to transected spinal cords to reestablish
useful motor function after SCI. For this purpose, we de-
veloped a novel DDS and tested its therapeutic potential
in vivo. Furthermore, we tested whether specific rehabili-
tation had the capability to reinforce motor function in
the SCT model after treatment with the semaphorin3A in-
hibitor. Our results can be briefly summarized as follows.
First, our newly developed DDS utilizing silicone sheets
provided continuous and stable drug delivery and there-
fore demonstrated potential clinical application. Second,
motor function recovery was considerably enhanced by
combining SM-345431, the novel semaphorin3A inhibitor,
with treadmill training, and this combined treatment
enabled paralyzed rats to perform continuous plantar step
walking on a treadmill with a BSS.
Osmotic mini pumps have been widely used for drug
delivery in animal models of SCI [20,45]. While these
pumps are excellent for controlling the drug release
dosage and the accurate positioning of drug delivery, this
method is too invasive for use in most patients. Therefore,
we developed a new silicone matrix preparation as a novel
DDS and showed that this novel DDS provided stable andFigure 7 Detailed kinematic analyses of hindlimb motor performance
analyses of hindlimb motor performance on a treadmill before and after re
(Rodent Robot 3000; Robomedica Inc.). BT represents before re-transection; A
the control group showed significant changes, the step cycle area parameter
attenuation of the step ability parameters was observed in the combined trea
were performed using t-test analyses. Data are presented as the mean ± S.E.Mcontinuous release of SM-345431 throughout the ex-
perimental period. In addition, because SM-345431 shows
a better stability in a silicone sheet than SM-216289 and
approximately the same semaphorin3A inhibitory activity
as SM-216289, we used SM-345431 instead of SM-216289
in the present study. As a result, significantly enhanced
axonal regeneration and motor function recovery were
observed after SM-345431 treatment, which is consistent
with our previous study using SM-216289 and osmotic
mini pumps [20]. Therefore, this novel DDS demonstrated
strong potential for future clinical use.
In this study, we examined the effects of a new sema-
phorin3A inhibitor, SM-345431, on axonal regeneration
and motor function recovery after SCT. Our data indicated
that SM-345431 administration using the novel DDS was
effective in promoting axonal regeneration and motor func-
tion recovery in vivo. However, consistent with the results
of our previous study using SM-216289, these effects were
moderate [20]. More importantly, we found that motor
function recovery was significantly enhanced by combin-
ing SM-345431 with extensive treadmill training (Figure 6).
This combined strategy enabled paralyzed rats to perform
continuous plantar step walking on a treadmill with a BSS.
Previous work has also demonstrated that intact or injured
axons in descending tracts and propriospinal circuits
can undergo spontaneous anatomical and physiological
remodeling after SCI [46,47] to allow the relay of informa-
tion through endogenous spinal circuits. Subsequently,
the novel propriospinal relay connections bypass the injury
epicenter to induce supraspinal control and some degree of
motor function recovery. This phenomenon has also been
observed following the irreversible interruption of long de-
scending tracts in mice [48]. Because SM-345431 treatment
without extensive treadmill training had limited effects
on anatomical reconstruction in the lumbar enlargementon a treadmill before and after re-transection. Detailed kinematic
-transection were performed and analyzed using a robotic device
T represents after re-transection. Although none of the step parameters in
s were attenuated in the SM-345431 group after re-transection. Further
tment group after re-transection. *P < 0.05 **P < 0.01. Statistical analyses
.
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recovery observed after SM-345431 treatment resulted
mainly from axon regeneration and limited anatomical
reconstruction. Enhanced axonal regeneration possibly
led to anatomical and physiological remodeling at the
lesion site and improved motor function recovery, which
is consistent with our previous findings using SM-216289
administered via osmotic mini pumps [20].
Interestingly, while axonal regeneration was not further
enhanced by combining SM-345431 treatment with exten-
sive treadmill training (Figure 2), motor function recovery
was significantly enhanced (Figure 6). Previous work dem-
onstrated that limited spontaneous axonal regeneration
occurs after SCI and that only some of the new axons are
useful for motor function recovery [49]. Thus, axonal
regeneration alone may not result in sufficient motor
function recovery unless these regenerated axons are
appropriately connected. We therefore hypothesized that
the regenerated axons induced by semaphorin3A inhibitor
treatment may exhibit substantially improved rewiring, in
terms of the formation of appropriate connections, follow-
ing extensive treadmill training. Indeed, motor function
recovery was enhanced significantly by combined treatment,
as paralyzed rats that received combined treatment were
able to perform continuous plantar step walking on a
treadmill with a BSS (Figure 6). Re-transectioning ex-
periments further suggested that the regenerated axons
at the lesion site and their rewiring contributed to the
enhancement in motor function recovery observed in
the treatment groups (Figure 7). We also observed that
some regenerated axons, such as 5-HT-positive raphe-
spinal tract axons, penetrated into the epicenter of the
lesion (Figure 2), and these regenerated axons may have
contributed to the reorganization of spinal circuitry at the
lesion site and enhanced motor function recovery in the
treatment groups [20]. Interestingly, we observed greater
attenuation of motor function after re-transection in the
combined treatment group (Figure 7). Taken together,
these data indicate that the regenerated axons achieved
substantial rewiring to the appropriate targets at the
lesion site, which was associated with the rehabilitation
performed in the combined treatment group [21].
Moreover, the enhanced motor function recovery was
only partially attenuated after re-transection in the treat-
ment groups. The results of these re-transection experi-
ments in the treatment groups, especially in the combined
treatment group, suggested that other factors, such as
reorganization of the lumbar spinal circuitry, also contrib-
uted to the enhancement of motor function recovery.
We also performed re-transection experiments in animals
that only received extensive treadmill training (without
SM-345431 treatment), and in these animals, only mini-
mum attenuation of motor performance after re-transection
was observed (data not shown). This finding furthersupports the mechanism proposed above. Taken together,
it is possible that specific rehabilitation enhances not only
the rewiring of the regenerated axons but also the
reorganization of the lumbar spinal circuitry [43]. Further-
more, in the combined treatment group, it is possible that
the effect of specific rehabilitation on the reorganization
of the lumbar spinal circuitry was the main contributor to
the enhancement of motor function recovery in the early
stage, while the effect on rewiring of the regenerated axons
was the main contributor to the enhancement of motor
function recovery during the later stage.
The results of c-Fos immunohistochemistry (Figure 5)
showed that extensive treadmill training induced plastic
changes at a level caudal to the injured site. Interestingly,
step ability on the treadmill was significantly correlated
with decreases in the numbers of c-Fos-positive nuclei
at a level caudal to the lumbar enlargement (Figure 5D).
Therefore, enhanced motor function recovery could be
partially the result of anatomical reconstruction of the
lumbar spinal cord, which is thought to be the location of
CPGs [50]. It is now widely accepted that supraspinal
drive of CPGs is required for locomotor function [51] and
that the intrinsic plasticity of CPGs allows some spontan-
eous motor function recovery even in the absence of signifi-
cant axonal regeneration [24,52]. Therefore, it is possible
that axon regeneration moderately enhanced motor func-
tion recovery in the SM-345431 treatment group, while
rewiring of the regenerated axons and CPG activation was
achieved by combining the SM-345431 treatment with
treadmill training.
Which segment of the lumbar enlargement is most
important for improved walking ability on a treadmill?
Reportedly, rhythmic bursts are related to flexor activity
at the L2 level and to extensor activity at the L5 level [50].
Treadmill training induces plastic changes in the transmis-
sion of group I pathways to extensors that consequently
support the recovery of weight-supported motion while
standing [53]. The present study showed that combined
treatment significantly altered c-Fos expression at the L4
and L5 levels (Figure 5B-C) and improved step height
(Figure 6D-E) and continuous plantar step walking on the
treadmill with a BSS (Figure 6G and Additional file 1).
However, while SM-345431 alone improved step ability,
this improvement did not lead to continuous plantar step
walking (Figure 6). Therefore, axon regeneration alone
might have only limited effects on the spinal cord extensor
pool, which could explain the limited motor function
recovery of SCT rats after SM-345431 treatment alone.
However, the combined treatment may have reestablished
the function of the extensor pool by rewiring the re-
generated axons and remodeling spinal circuits. As a
result, important motor functions, such as continuous
plantar step walking (on a treadmill with a BSS), may have
been reestablished in SCT adult rats in the combined
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with specific rehabilitation is a reasonable and promising
approach to the treatment of SCI.
Other possible mechanisms underlying motor function
recovery could include remyelination and angiogenesis.
We noticed that, with increases in afferent sensory input,
the step lengths of the SM-345431 groups while walking
on the treadmill exhibited a linear and gradual improve-
ment throughout the experimental period. The animals
treated with SM-345431 showed enhanced remyelination
at the lesion site (Figure 4E-J), which could be relevant to
a recent study reporting the effects of semaphorin3A on
myelination [36]. In general, myelination significantly
increases conduction velocity (sometimes up to 100-fold
[54]), which results in increased motor function. Thus,
remyelination after SM-345431 treatment may have also
partially contributed to the enhancement of motor function
recovery on the treadmill. Angiogenesis also plays an im-
portant role in reducing secondary damage and enhancing
tissue repair after SCI, and the extent of angiogenesis corre-
lates with the extent of axon regeneration after SCI [33].
Angiogenesis was significantly enhanced after SM-345431
treatment alone, although combined treatment did not
further enhanced this effect statistically (Figure 4A-D).
Therefore, angiogenesis may also have contributed to
motor function recovery. Interestingly, at the end of the ex-
perimental period (3 months post-injury), the incremental
effects of the treatment on motor performance, specifically
in terms of step height and step cycle area, tended to be
more robust in the SM-345431 treatment group than in
the combined treatment group (Figure 6D-F). These data
indicate that combined treatment may also have expedited
motor function recovery and decreased the overall time
needed for recovery.
Conclusions
Collectively, our data demonstrate that the administration
of SM-345431 via a novel DDS utilizing silicone sheets
significantly enhanced axonal regeneration, remyelination
and angiogenesis, thereby promoting motor function
recovery after SCT in adult rats. Additionally, combining
SM-345431 with extensive treadmill training resulted
in improved motor function recovery that included con-
tinuous plantar step walking on a treadmill with a BSS.
This comprehensive effect of combined treatment presum-
ably resulted from the reinforcement of spinal networks in
the caudal spinal stump and the rewiring/refinement
of regenerated axons. Thus, combining semaphorin3A
inhibitor treatment with extensive treadmill training has
great potential as a new treatment for SCI. In addition,
this study highlights the importance of combining treat-
ments that promote axon regeneration with specific and
appropriate rehabilitations that promote rewiring for the
effective treatment of SCI.Methods
Overall experimental outline
Rats were randomly divided into the following three
experimental groups: 1) untrained + placebo, 2) untrained +
SM-345431 and 3) trained + SM-345431. SCT was per-
formed, and SM-345431 or placebo was administered at
the lesion site via the newly developed DDS, which is
described in detail below. Starting 1 week post-injury,
treadmill training commenced with a BSS. Kinematic
tests were performed monthly for 3 months after SCT using
a rodent robotic device (Rodent robot 3000, Robomedica
Inc.) that primarily assessed the performance of plantar
stepping on a treadmill. Treadmill training was continued
throughout the experimental period.
Animals and surgical procedures
A total of 53 adult female Sprague-Dawley rats (200-250 g,
10-12 weeks old) were used in this study (3 rats died during
the experimental period and were excluded from the
statistical analysis). All procedures were approved by the
experimental animal care committee of Keio University,
School of Medicine and Murayama Medical Center (ap-
proval #12-8). All rats were anesthetized with an intra-
peritoneal injection of ketamine (100 mg/kg)/xylazine
(10 mg/kg). The spinal cord at the level of the T10 lamina
was exposed by T10 laminectomy, and the dorsal dura
mater was opened. The exposed spinal cord was cut along
the inner edge of the vertebra with a sharp micro-scissor.
Two more cuts were made at the gap of the transected
spinal cord by a scalpel to ensure total transection. SM-
345431 or placebo was administered to the transected site
via the newly developed DDS as described in detail below
(Figure 1G-I). After these procedures, the back muscles
and skin were closed. Rats were kept warm in an incubator
(37°C) after surgery. To prevent dehydration in the rats,
10 ml of saline was subcutaneously injected daily until day
7. Ampicillin (0.4 g/kg) was also injected intramuscularly
daily to prevent infection until day 7. The bladder was
evacuated manually until autonomous emptying of the
bladder was achieved. The re-transection procedure was
performed at the same level as the primary SCT (15 rats
total; 5 rats from each group). Kinematic data were re-
corded using similar procedures prior to re-transection
surgery (on the same day) and on the day following re-
transection surgery. For CST tracing, 10% BDA was
injected as follows. Nine weeks after SM-345431 or
placebo administration, BDA (10000 MW, Molecular
Probes) was injected into six different sites of the sen-
sorimotor cortices of the rats under general anesthesia
(site 1: 2.0 mm lateral, 0 mm to bregma; site 2: 2.0 mm
lateral, 2 mm posterior to bregma; site 3: 2.0 mm lateral,
4 mm posterior to bregma; site 4: 4 mm lateral, 0 mm to
bregma; site 5: 4 mm lateral, 2 mm posterior to bregma
and site 6: 4 mm lateral, 4 mm posterior to bregma). For
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(1.2 mm and 1.6 mm), and 3 μl of 10% BDA was injected at
a rate of 0.15 μl/min using a micro-injector. Three weeks
after the BDA injection, rats were sacrificed and used for
immunohistochemistry.
Growth cone collapse assay and collagen co-culture assay
The growth cone collapse assay and collagen co-culture
experiments were performed as previously described [20].
To examine the effects of SM-345431-silicone, small pieces
(2 × 1 × 0.3 mm; approximately 1 mg containing 1 μg of
SM-345431) of the SM-345431-silicone or control-silicone
were placed in a collagen gel adjacent to E8 chick DRGs
and COS7 cell aggregates, as shown in Figure 1C.
Drug delivery system
A novel matrix silicone preparation was developed to
allow continuous drug delivery at the site of injury. The
amount of drug released from this matrix silicone prepar-
ation in vitro was measured as described in Figure 1. Matrix
silicone sheets (0.3 mm thick) containing SM-345431 were
trimmed into 3-mm-square pieces to fit into the opened
dura. After SCT, one piece of silicone sheet was placed on
the transected spinal cord gap so that it could act on the
spinal cord directly. Silicone sheets of the same size that
did not contain SM-345431were used for the control
group.
Training protocol
A robotic device (rodent robot 3000, Robomedica Inc.) [55]
was used to train the SCT rats. Briefly, the device consisted
of a computer-controlled BSS, two lightweight robotic arms
and a treadmill with variable motorized speeds. The ankles
of the hindlimbs of rats were held with a pair of releasable
rope cuffs, which were then secured to robotic arms
to track ankle trajectory in the horizontal and vertical
directions. A computer-controlled body support arm
was used to control the load that was applied to the
hindlimbs and to maintain body equilibrium. Rats were
secured in a cloth vest and attached to the body support
arm with a hook-and-loop fabric. Hard rope cuffs were
attached to the hindlimbs of rats with the robotic arm
during training.
In our pilot study, we found that it was possible to
train spinal cord-transected rats soon after SCT via
voluntary walking evoked by sensory input. Additionally,
improvements in motor performance were more obvious
when the treadmill training was initiated at earlier time
points after SCT. Therefore, training was initiated as early
as 1 week after SCT. The fixed parameters were set
at 50% body weight support (BWS), 20 min/day and
5 days/week. The animals were adapted to the training via
increasing velocity; a velocity of 1 cm/s was used in the
first week, and then the velocity was increased by 2 cm/severy 2 weeks for the first 2 months after injury (i.e.,
1 cm/s to 3 cm/s to 5 cm/s). In the first week of training,
rats frequently did not adapt to the acceleration of the
treadmill, and this resulted in dragging of the hindlimbs.
Once the rats dragged their hindlimbs and stopped walking
on the treadmill, a trainer brought their bodies back to the
original walking position. The step ability of SCT rats on
the treadmill improved gradually over the course of the
first 2 months following injury. However, this improve-
ment was attenuated at time points later than 2 months
after injury. Hence, at the time points later than 2 months
after injury, the velocities of the treadmill were adjusted to
5 to 9 cm/s according to the improvement observed in the
hindlimb motion of the rats.
Detailed motor function analysis using kinematics
To evaluate the locomotor capability of SCT rats in detail,
the aforementioned robotic device was employed. Each
robotic arm tracked the two-dimensional movement of
the ankle, and the trajectory of the ankle movement was
then recorded on a computer for kinematic analyses. Not
all the rats were able to walk by themselves on the treadmill
by the last time point of the experiment. Therefore, when
performing the tests, the degree of BWS and treadmill
speed were titrated to obtain the maximum walking
performance on the treadmill. As a result of this titration,
the behavioral tests were performed at 70% BWS and a
treadmill velocity of 1 cm/s each month after SCT. The
duration of testing was 1 min per rat to minimize training
effects during testing. The methods of previous reports
[44,56] were followed with slight adaptations. Briefly, the
ankle trajectory in each plane was recorded by the robotic
arm and a computer. Then, the toe off (TO) and paw con-
tact (PC) events in each step cycle were identified using
Rodent Robot 3000 software. All kinematic characteristics
were obtained when TO and PC were identified; as a re-
sult, parameters such as the duration phase, the swing
phase of the step cycle and the length and height of the
step were calculated. The number of animals used in these
behavioral tests was 32 (control: n = 9, SM-345431: n = 12,
combined: n = 11).
Immunohistochemistry
Twelve weeks after SCT, rats were deeply anaesthetized by
an intraperitoneal injection of 14% chloral hydrate and
then perfused intracardially with 4% paraformaldehyde
(PFA) in 0.1 M phosphate-buffered saline (PBS). The
spinal cord tissues were dissected and post-fixed in 4%
PFA (24 h) and placed in 10% sucrose in 0.1 M PBS
(24 h) followed by 30% sucrose in 0.1 M PBS (24 h). All the
rats other than 3 rats died during the experimental period
were used for the histological analysis. Segments of spinal
cords were embedded in Optimal Cutting Temperature
compound (Tissue Tek) and stored at -80°C. Frozen spinal
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sections. For diaminobenzidine (DAB) staining, sections
were washed with 0.1 M PBS and then presoaked for
30 min in 0.03% H2O2 with methanol. After an additional
presoak in TNB (0.10 M Tris-HCl, 0.15 M NaCl, 0.5%
BMP) for 60 min, sections were incubated at 4°C with
rabbit anti-GAP43 (1:300; Millipore), mouse anti-rat
RECA-1 (1:500; Serotec) or rabbit polyclonal anti-synapsin-
1 (1:300; Chemicon) for 24 h. Subsequently, the sections
were washed in 0.1 M PBS and incubated with biotinylated
secondary antibodies (1:1,000; Jackson Immunoresearch)
for 1 h. Next, the sections were washed and then incu-
bated with an avidin-biotin complex (ABC) (Vectastain
Elite ABC Kit, Vector Laboratories) in TNB (1:100) and
visualized using DAB (Sigma). Sections were rinsed in PBS,
dehydrated using ethanol and xylene and cover-slipped
with permount. To identify 5-HT-positive axons that pene-
trated into the scar tissue area after the treatment, we used
a previously described double-staining method [28]. 5-HT
was visualized using goat anti-serotonin (5-HT) antibody
(1:500; ImmunoStar) and DAB with nickel-glucose oxidase,
which produced a black stain. Sections were washed and
then incubated with rabbit monoclonal anti-glial fibrillary
acidic protein (GFAP; 1:1,000; BD Bioscience Pharmingen)
and visualized with DAB, which produced a brown stain.
Following these procedures, we identified the range of the
scars and quantified the number of 5-HT-positive axons
that penetrated into the scar tissue area. To evaluate the
status of axonal myelination, immunofluorescent double
staining was performed using rabbit anti-GAP43 (1:1,000;
Millipore) and rat monoclonal anti-MBP (1:50; Abcam)
antibodies. Immunohistochemical analysis for c-Fos in
spinal neurons was performed using procedures similar
to those previously described [24,41,43]. Briefly, rats
were trained using the aforementioned training method of
continuous hindlimb bipedal stepping. After 45 min of
continuous hindlimb bipedal stepping at 3 cm/s with 50%
BWS with a hard nylon rope attachment, rats were
allowed a 60-min rest. Subsequently, the rats were anes-
thetized and perfused intracardially with 4% PFA in PBS.
After perfusion, the spinal cords were dissected, post-fixed
for 24 h at 4°C and cryoprotected in 30% sucrose in PBS
for 3 days. The L1-L5 segments were mounted and frozen,
and 20-μm-thick axial sections were cut using a cryostat.
All sections were pretreated with 0.03% H2O2 and metha-
nol for 30 min and then incubated with rabbit polyclonal
anti-c-Fos antibody (1:200; Santa Cruz Biotechnology) for
24 h (at 4°C). Subsequently, the sections were washed
in 0.1 M PBS and incubated in biotinylated secondary
antibody (1:1,000; goat antibody against rabbit; Jackson
ImmunoResearch) for 1 h. The remaining procedures
were identical to those performed for DAB staining, as
described above. All images were obtained using either
an Axioskop 2 Plus microscope (Zeiss) for DAB stainingor a LSM510 confocal microscope (Zeiss) for immuno-
fluorescent staining.
Electron microscopic analysis
For electron microscopic analysis, rats from the 3 groups
were sampled 72 days after injury. Rats were perfused
with 4% PFA in PBS, and the spinal cords were dissected
and post-fixed with 2.5% glutaraldehyde overnight at 4°C.
After 90 min of fixation with 0.5% osmium tetroxide, the
spinal cords were dehydrated with ethanol, acetone and
QY1 and then embedded. Ultrathin sections at the epicen-
ter of the lesion sites were prepared at a thickness of 80 nm
and stained with uranyl acetate and lead citrate for 15 and
12 min, respectively. The sections were observed with a
transmission electron microscope (JEOL model 1230),
and images were acquired using Digital Micrograph 3.3
(Gatan Inc.).
Quantitative immunohistochemistry analyses
Immunohistochemical image analyses were performed for
all sections of each animal using microscopy, and quanti-
tative analyses were performed by an examiner who was
blind to the identities of the animals. Each value is pre-
sented as the average value per section (unless otherwise
indicated). The number of animals used for quantitative
analysis of each staining set ranged from 15 to 21 (5 to
7 animals per group). To quantify the area of GAP-43-
positive axons, 5-HT-positive axons and RECA-1-positive
vessels, sagittal sections of the spinal cord at the injury site
(approximately 1.2 cm in length) were scanned with a
CCD camera (DXC-390; Sony). Pictures of the sagittal
sections at 1 mm to 3 mm rostral and 1 mm to 3 mm
caudal from the injury epicenter were captured for quanti-
tative analyses. The images were analyzed with a Micro
Computer Imaging Device (MCID; Imaging Research
Inc.). Threshold values were maintained at constant levels
for all analyses. 5-HT axons that penetrated into the scar
tissue were counted manually. For image analysis, c-Fos-
positive (c-Fos+) nuclei from all sections was superimposed
onto Molander’s cytoarchitectonic maps of the rat thoracic
and lumbosacral cord [57]. The expression of synapsin-1
was examined within lamina IX of the L1-L5 segments of
the spinal cord using transverse sections and DAB staining.
For the quantification of BDA tracing, we followed the
methods reported previously [58,59]. The number of
CST-positive axons at each distance from the lesion was
divided by the number of CST-positive axons at the level
of C1 for standardization.
Statistical analyses
For statistical analyses, one-way analyses of variance (one-
way ANOVA) and Bonferroni post hoc tests were primarily
employed to determine significance. Significance was
determined using P-values, and the data are presented
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staining, data were analyzed with the Kruskal-Wallis H
test. Behavioral data after re-transection were analyzed
with t-tests.
Additional file
Additional file 1: Video Representative movies of the detailed
kinematic analysis of hindlimb motor performance on a treadmill at
the end of the experimental period. Plantar step walking with a BSS
was not observed in control group animals (A). Limited plantar step
walking with a BSS was observed in SM-345431 treatment group animals
(B). Significantly enhanced plantar step walking with a BSS was observed
in the combined treatment group animals. All animals in the combined
treatment group continued plantar step walking with a BSS for at least
30 min (C).
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